TABLE 4.
Serum vibriocidal titers of vaccineesa
| Immunogen | n | GM titer (range) at indicated day after immunization
|
||||
|---|---|---|---|---|---|---|
| 0 (preimmunization) | 28 | 42b | 70 | 230 | ||
| DeALPS-CT-1 | 19 | 11 (5–32) | 1,090 (320–6,400) | 884 (220–6,400) | 629 (20–3,200) | 330 (64–1,280) |
| DeALPS-CT-2 | 19 | 15 (5–128) | 1,645 (640–12,800) | 1,405 (640–12,800) | 1,253 (400–6,400) | 588 (128–3,200) |
| DeALPS | 19 | 17 (5–128) | 29 (5–200) | 30 (5–200) | 32 (5–200) | 33 (8–128) |
| Cellularc | 18 | 15 (5–40) | 3,981 (3,200–12,800) | 2,343 (1,600–6,400) | 1,835 (800–6,400) | 909 (200–3,200) |
a
V. cholerae O1 strain 075, serotype Inaba, was the target organism.
b
Blood sample taken and volunteer reinjected with the same vaccine.
c
Wyeth-Ayerst Laboratories, containing 4 × 109 organisms each of V. cholerae O1 serotypes Inaba and Ogawa.